Gli genes in development
The Hh/Ci pathway: Ci proteolysis is regulated by Hh signaling
The Hh gene was ®rst identi®ed in a screen for segment polarity mutations in the fruit¯y Drosophila melanogaster (Nusslein-Volhard and Wieschaus, 1980) . In mammals, three Hh proteins are known, Sonic hedgehog (Shh), Indian hedgehog and Desert hedgehog (Echelard et al., 1993) . Shh has an important role during embryonic development, directing pattern formation and inducing cell proliferation in numerous tissues, including the central nervous system (CNS), limbs, somites, skeleton and skin.
Since there have recently been several detailed reviews of the Hh pathway (Hammerschmidt et al., 1997; Goodrich and Scott, 1998; Ingham, 1998) in this review we will primarily focus on the role of Ci/Gli genes in this pathway. In Drosophila, Hh signaling has been most extensively studied in the embryonic epidermis and imaginal discs, groups of immature cells set aside during larval development that give rise to all mature appendages. Imaginal discs can be divided into two compartments, anterior (A) and posterior (P), and an additional unique domain at the compartment boundary ( Figure 1 ). In wing discs, cells in the P compartment express Hh, while A cells express Ci and Hh receptors. Hh induces Decapentaplegic (Dpp) a member of the TGF-b family of secreted molecules in A cells near the A/P boundary. Dpp protein then acts as a secondary, longer-range signal to activate target genes in both the A and P compartments (Basler and Struhl, 1994; Tabata and Kornberg, 1994) .
Using monoclonal antibodies that recognize either the N-or C-terminus of Ci protein, it was shown that Ci is present in two forms, a full-length form, Ci-155, detected primarily in the cytoplasm, and a C-terminally truncated nuclear form, Ci-75, that is generated by proteolysis of Ci-155 (Aza-Blanc et al., 1997) . These two forms of Ci are unequally distributed in the A compartment: Ci-155 levels are high near the A/P boundary, while Ci-75 is distributed more evenly ( Figure 1a ). Both forms contain ®ve tandem DNAbinding zinc-®nger domains; however, Ci-75, which functions as a transcriptional repressor (Aza-Blanc et al., 1997) , lacks the acidic activation domain and binding site for the co-activator CBP which are located in the C-terminus of Ci-155 (Alexandre et al., 1996; Akimura et al., 1997) .
The proximity of Ci-155 localization to Hh expressing cells, and the fact that Ci transcription is independent of Hh (Alexandre et al., 1996) suggests that Hh may exert post-translational control over Ci-155 localization. In A cells near the A/P boundary, Hh interacts with two transmembrane proteins, Patched (Ptc) and Smoothened (Smo) (Figure 1c ). Ptc, a multipass transmembrane protein, binds to Hh and in its absence antagonizes Hh signaling by inhibiting Smo activity (reviewed in Goodrich and Scott, 1998) . Smo, a G-protein coupled transmembrane receptor-like protein, is required to activate Hh target genes in response to Hh signaling, although it does not bind to Hh (Stone et al., 1996; Chen and Struhl, 1998) . Hh binding to Ptc relieves its repression of Smo, and leads to inhibition of Ci proteolysis, which results in Ci-155 accumulation. A reciprocal antagonism between Hh and Ptc activities provides negative feedback of the pathway; Hh signaling relieves the repression of ptc transcription by Ptc activity, ultimately leading to Ptc protein upregulation, which further restricts the range of Hh signaling by binding and sequestering Hh protein (Chen and Struhl, 1996) .
Ci-155 and Ci-75 have both unique and common targets: hh appears to be primarily repressed by Ci-75 and ptc activated by Ci-155, while dpp responds to both forms (MeÂ thot and Basler, 1999 ). An important feature of the model for post-translational regulation of Ci by Hh (see Figure 1) is that Ci can either activate or repress Hh target genes depending on the concentration of Hh present. Thus, the activity of Figure 1 The Hh/Ci signaling pathway in¯y wing imaginal discs. (a) Relative levels of Ci-75 and Ci-155 protein in the A compartment and A/P boundary region compared to Hh levels in the P compartment. (b) Schematic of wing imaginal disc showing the expression of Hh, Ci, Dpp and ptc in the anterior (A) and posterior (P) compartments. Dashed line in A compartment indicates the border of the A/P boundary domain that expresses Dpp. Ci is only expressed in the P compartment, and is repressed in the A compartment by En activity, allowing hh transcription (Schwartz et al., 1995) . In A compartment cells at a distance from Hh expressing P compartment cells, the majority of Ci-155 is constitutively processed into Ci-75, which acts as a repressor of the Hh target genes dpp, and hh itself. In A cells near the P compartment boundary that receive high levels of Hh, proteolysis of Ci-155 to Ci-75 is partially inhibited, and full-length Ci-155 accumulates and is thought to enter the nucleus and activate Hh targets such as dpp and ptc. (c) Enlargement of representative cells in either the P compartment that are not exposed to Hh or A/P boundary cells that receive Hh (blue circles). Broken arrow indicates possible further Hh signaling required to promote Ci maturation. This schematic illustrates the many potential points of in¯uence over Ci-mediated Hh signal transduction. See text for details. Figure is modi®ed from Kalderon (1997) and Ruiz i Altaba (1997) some target genes may be controlled by the ratio of Ci-155 to Ci-75, while other target genes might depend on the presence of the speci®c form of Ci. Recent evidence also suggests that Hh signaling is required not only to inhibit Ci proteolysis, but also to promote maturation of Ci-155 to a full-¯edged activator, perhaps by further in¯uencing phosphorylation and/or nuclear tracking (Ohlmeyer and Kalderon, 1998; MeÂ thot and Basler, 1999 ).
Cytoplasmic control points and possible pathway convergence
In A cells, proteolysis of Ci-155 appears to depend on Protein kinase-A (PKA) mediated phosphorylation of Ci protein (Jiang and Struhl, 1995; Li et al., 1995; Chen et al., 1999b; Price and Kalderon, 1999) . Phosphorylated Ci may be a substrate for Slimb (Slmb), an F-box/WD40-repeat protein with homology to a yeast protein involved in degradation of cell cycle regulators (Jiang and Struhl, 1998) . It has been proposed that Slmb might target Ci for processing via the proteosome pathway in a manner analogous to NF-kB processing (Jiang and Struhl, 1998) . Interestingly, Slmb also appears to play a role in the wingless (wg) pathway, targeting armadillo protein for degradation (Alberle et al., 1997) .
In the cytoplasm, Ci-155 is part of a large microtubule-anchored protein complex that also contains the Fused (Fu) serine/threonine kinase, the kinesin-related Costal-2 (Cos2) protein, and possibly Suppressor of fused (Su (Fu)) ( Figure 1c ) Robbins et al., 1997; reviewed in Johnson and Scott, 1997; Ruiz i Altaba, 1997; Kalderon, 1997; Goodrich and Scott, 1998) . Hh signaling promotes the dissociation of the Cos2/Fu/Ci complex from microtubules, which results in inhibition of Ci proteolysis. Cos2 and Fu are both phosphorylated in response to Hh, while Ci and possibly Smo are phosphorylated in the absence of Hh (TheÂ rond et al., 1996; Robbins et al., 1997) . It seems possible that some of the phosphatase and/or kinase proteins also function in other signaling pathways, thus the status of these other pathways could in principle aect Hh signaling and provide context-dependent cellular responses. Clearly, the complex regulation of Ci activity through subcellular localization, proteolysis and selective phosphorylation allows for many levels of control over Ci activity (see Figure 1) .
While full-length Ci likely functions as a transcriptional activator, it has yet to be detected in the nucleus of cells in vivo, although recently a Hh responsive cell line has been identi®ed in which Ci-155 can be detected in both the cytoplasm and nucleus (Chen et al., 1999a) . It is possible, however, that levels of Ci-155 below detectability can activate target genes, consistent with the multiple mechanisms that are in place to restrict nuclear entry of Ci-155 in cells far from Hh (Chen et al., 1999a) . In fact, not all Ci is proteolyzed to Ci-75 in A cells; the`residual' Ci-155 that escapes from proteolysis is prevented from activating target genes by its retention in the cytoplasm and active nuclear export (Aza-Blanc et al., 1997; Chen et al., 1999a) .
The Gli family
The ®rst vertebrate Gli gene to be discovered was human GLI1 (also known as GLI), based on its ampli®cation in a glioblastoma (Kinzler et al., 1987) . All three vertebrate Gli proteins (Gli1, Gli2 and Gli3) have high homology to Ci and to the C. elegans sex determination protein Tra-1 (Zarkower and Hodgkin, 1992) in the zinc-®nger domain, and limited homology in a number of domains outside this region ( Figure 2 ). Recent genetic and biochemical experiments have shown that Gli genes have a conserved role in the Hh Figure 2 Conservation of Ci/Gli protein structure. Schematic comparing the domain structures of mouse Gli proteins with Drosophila Ci. The highest conservation is in the zinc-®nger domain (red), with little homology outside this region except for a 55 ± 57 a.a. domain in the N-terminus (purple) in which 88% of the residues are identical amongst mouse Glis and 69% between Glis and Ci. Mouse Gli proteins contain a number of additional small conserved regions (8 ± 43 a.a.) within the C-terminus (yellow). Potential PKA sites (green) are conserved between Glis and Ci, although Gli1 contains one less site. The most C-terminal conserved domain (asterisk above Gli1) is similar to the VP-16-like activator domain described by Yoon et al. (1998) . Left side is N-terminus. Domain positions are approximate. Figure provided by Brian Bai pathway in vertebrates. However, it is also likely that the way in which the Gli proteins function might be dierent for each Gli protein and that Gli genes might play roles independent of Hh signaling during development.
Gli1 is an activator, while Gli2 and Gli3 contain both activation and repression domains Using Ci protein processing as a model, all three vertebrate Gli proteins have been tested for separate functional domains. C-terminally truncated forms of both Gli2 and Gli3 that resemble the Drosophila Ci-75 protein can repress reporter gene expression in cell lines or Shh targets in vivo (Dai et al., 1999; Ruiz i Altaba, 1999; Shin et al., 1999) . In contrast to Gli2 and Gli3, Gli1 does not appear to possess an N-terminal repressor domain, instead functioning only as an activator of transcription in its full-length form. Fulllength Gli2, and to a lesser extent Gli3, proteins also can activate reporter gene expression in cell lines (Shin et al., 1999; Sasaki et al., 1999) , and Gli2 can induce motoneuron dierentiation in frog embryos (Ruiz i Altaba, 1998 ). These studies demonstrate the potential for Gli2 and Gli3 to have activator and repressor activities, while Gli1 might only function as an activator. For Gli2 and Gli3, additional regulatory domains in the N-terminus proximal to the zinc-®nger domains may also exist, since deletion of N-terminal sequences produces proteins with a constitutive strong activation function, both in vitro and in vivo (Sasaki et al., 1999) .
Are Gli proteins processed in vivo?
There has been scant, and sometimes con¯icting, evidence that Gli proteins are proteolyzed in vivo. In one study, Western blot analysis of whole mouse extracts detected only a single band for Gli1 and multiple bands for Gli3, suggesting that only Gli3 might be processed (Dai et al., 1999) . Transfection of tagged full-length Gli proteins into cell lines has shown that multiple small protein forms can be detected for Gli2 and Gli3, while Gli1 only shows one band in the mouse but multiple bands in frog (Dai et al., 1999; Ruiz i Altaba, 1999) . Moreover, C-terminally-truncated forms of all three Gli proteins can be detected in both the cytoplasm and the nucleus of cultured cells and transfected frog embryos Dai et al., 1999; Ruiz i Altaba, 1999; Shin et al., 1999) . It has also been shown in cell lines that formation of a smaller form of Gli3 depends on PKA, and full-length Gli3 can bind to CBP, while Gli1 transactivation function requires neither (Dai et al., 1999) . One diculty in interpreting these data is that experiments have been performed in a variety of dierent contexts (dierent cell lines and in vivo). In addition, transfection experiments can only illustrate potential mechanisms of Gli protein function but not the actual mechanisms employed in vivo.
Gli genes have both unique and overlapping roles downstream of Shh in vertebrates
Shh is expressed in numerous tissues known to have polarizing activities during development. Shh expression is ®rst detected in the node, and later in the notochord,¯oor plate of the neural tube, and in the zone of polarizing activity (ZPA) in the limb buds (Echelard et al., 1993; Krauss et al., 1993; Riddle et al., 1993; Roelink et al., 1994) . Shh is also expressed in tooth, skin, and a number of other tissues where inductive interactions are known to occur during development. In mouse, two Ptc genes have been identi®ed, Ptc1 and Ptc2 (Goodrich et al., 1996; Motoyama et al., 1998a; Carpenter et al., 1998) . As a rule, Gli1 and Ptc1 expression are largely, if not entirely, restricted to proliferating cells adjacent to Shh-expressing tissues, while Gli2 and Gli3 are more broadly expressed in proliferating cells in regions more distant to Shh, with Gli3 being the most distant (Hui et al., 1994; Stone et al., 1996; Marigo et al., 1996; Platt et al., 1997) . Ptc2 expression overlaps Ptc1 in some regions of the embryo (Carpenter et al., 1998; Motoyama et al., 1998a) .
Mouse Shh mutants have a severe embryonic phenotype that includes the absence of anterior/ posterior limb polarity, lung mesoderm, and virtually all ventral cell types (e.g., motoneurons) in the CNS (Chiang et al., 1996; Litingtung et al., 1998) . Mouse Ptc1 mutants have numerous defects consistent with its requirement both as a repressor of Shh targets and a receptor mediating some aspects of Shh signal transduction (Goodrich et al., 1997) . Of the three vertebrate Gli genes, the ventrally restricted expression of Gli1 in the CNS suggests its involvement in the Shh pathway. Consistent with this, Gli1 is a transcriptional target of Shh signaling in vertebrates, and Gli1, like Shh, can induce the expression of some ventral cell types when expressed in the dorsal CNS, whereas Gli2 and Gli3 cannot (Hynes et al., 1997; Lee et al., 1997) . The role of PKA is also conserved in vertebrates, as mis-expression of a dominant-negative PKA dorsally can induce ventral cell types and the Shh targets Gli1 and Ptc1 in the CNS (Epstein et al., 1996; Hammerschmidt et al., 1996) . Interestingly, although Gli1 is sucient to induce Shh targets, mice homozygous for a mutation that removes most of the zinc-®nger domains (Gli1 zfd ) develop normally, indicating minimally that the DNA binding activity of Gli1 is not required for Shh signaling (Matise et al., 1998; Park et al., submitted) . In contrast, Gli2 zfd/zfd mutants exhibit a number of defects consistent with a requirement downstream of Hh in the ventral CNS (Ding et al., 1998; Matise et al., 1998) , as well as defects in development of the vertebrae, lungs and bones (Mo et al., 1997; Motoyama et al., 1998b) . Most Gli1 zfd/zfd ; Gli2 zfd/+ mutants die around birth and have CNS and lung defects that are similar to, but milder than Gli2 mutants (Park et al., submitted). However, motoneurons are induced in Gli1/2 double homozygotes, and anterior/posterior limb patterning is largely normal (Park et al., submitted; Matise et al., 1998) , suggesting that not all events that require Shh also require Gli1 and Gli2. These double mutant studies suggest that Gli2 is primarily required for induction of certain Shh responsive cell types, while Gli1 is only required in certain tissues in combination with Gli2 in the mouse.
In humans several dierent genetic diseases involve mutations in Gli3, including Greig's cephalopolysyndactyly (GCPS), Pallister-Hall syndrome (PHS), and postaxial polysyndactyly type A (PAP-A) (reviewed in Biesecker, 1997) , and in mouse a deletion including most of Gli3 is responsible for the extra-toes J (Xt J ) mutation which has a similar phenotype to GCPS (Vortkamp et al., 1992; Hui and Joyner, 1993; KalSuske et al., 1999) . Some aspects of the phenotype of Gli3 xtJ mutants indicate a role for Gli3 in the repression of Shh expression in the developing CNS and limbs (Marigo et al., 1996; Buscher et al., 1997; Ruiz i Altaba, 1998) , although in vitro Gli3 can activate transcription through a Gli1 promoter region DNA fragment (Dai et al., 1999) .
The relatively mild phenotyes of single mouse Gli mutants compared to their widespread expression in embryos suggests there is redundancy between Gli gene function. Consistent with this, Gli2
; Gli3 7/7 mutants have more severe skeletal abnormalities than either mutant alone (Mo et al., 1997) , and in Gli1/2 double homozygotes, the lungs are more severely aected than in either single mutant (Park et al., submitted) . If Gli proteins embody both positive and negative functions like Ci, then in the CNS, for example, Gli1 may function only as an activator that is sucient, but not required, for Shh target-gene transcription, and this function could be redundant ventrally with activation functions of Gli2 and Gli3. Also, any putative repressor function for Gli2 in the dorsal CNS could be redundant with Gli3 (Figure 3 ).
Shh/Gli pathway divergence
Two important questions remain unanswered. Is there a pathway downstream of Shh that does not involve/ Figure 3 A model for Gli-mediated cell fate induction in the ventral CNS in vertebrates. Three regions representing dierent Shh signaling outcomes are depicted. Shh (blue circles) from the notochord interacts with the overlying¯oor plate (FP) and converts Gli2 to an activator by repressing proteolytic conversion to a repressor. Gli2 activates Hnf3b, and possibly Gli1 and Ptc transcription, although Gli1 and Ptc expression are detected in the ventral CNS of Gli2 7/7 mutants but at lower levels (Ding et al., 1998; Matise et al., 1998) . Hnf3b then induces Shh expression in FP cells. Shortly after its induction, Shh expression in the FP becomes independent of Gli genes as they are down-regulated in the FP after neural tube closure. In motoneurons, it is possible that a Gli-independent pathway exists, since the DNA binding activities of Gli1 and Gli2 are not required for motoneuron induction or CoupTFII reporter gene activation (Ding et al., 1998; Matise et al., 1998; Krishnan et al., 1997) . Another pathway downstream of Shh may involve a PP-2A like phosphatase and other factors (X) (see text for further details). In dorsal CNS regions where no Shh is expressed, Gli2 and Gli3 proteins are constitutively processed into repressors that inhibit Shh (and possibly other) gene expression. It is not clear whether Gli repressors are also produced in ventral regions. If they are, their function may be superceded by small amounts of Gli activator proteins (as with Ci-155 and Ci-75 in¯ies) or alternatively their repressor activity could somehow be inhibited. D=dorsal, V=ventral require Gli genes? Conversely, is there a function for Gli genes independent of Shh signaling?
Several recent studies raise the possibility of a Gliindependent Shh pathway. Analysis of Hh-dependent regulatory regions for the wg gene in¯ies and the CoupTFII gene in mice has revealed that they do not contain consensus Ci binding sites (Krishnan et al., 1997; Lessing and Nusse, 1998) . Interestingly, Shhdependent activation of the motoneuron-speci®c CoupTFII promoter DNA fragment instead appears to involve a PP-2A-like phosphatase (Krishnan et al., 1997) . Loss-of-function studies in mice also support the possibility of a Gli-independent Shh signaling pathway. Double Gli1/2, Gli2/3 and Gli1/3 mutants are less severely aected than Shh mutants in most tissues except the lungs (Mo et al., 1997; Matise et al., 1998; Park et al., submitted; unpublished results) . Although triple Gli1/2/3 mutants have not yet been studied, in many regions of the embryo where Shh is expressed, only one or two Gli genes are detected. Thus, it seems unlikely that triple mutants will have a similar phenotype to Shh mutants. In addition, analysis of talpid 3 chick mutants suggests a Gli-independent Shh pathway in limb development (Lewis et al., 1999) .
The possibility that Gli genes possess activities independent of Shh signaling is raised by the observation that Gli2 and Gli3 are expressed widely in many regions of the embryo that are far from Shh sources (Hui et al., 1994) . This also appears to be true for Ci in¯ies. In addition, defects in Gli2 and Gli3 mutant mice are found in some regions of the embryo that are not likely to result from loss of Shh signaling (Grindley et al., 1997) . However, if Gli2 and Gli3 inhibit the Shh pathway in these regions, the defects could be due to inappropriate activation of Shh targets.
Gli genes in cancer
Since the identi®cation of GLI1 as an ampli®ed gene in a human glioblastoma, it has also been found to be ampli®ed in a variety of cancers, although often at a low frequency (Kinzler et al., 1987; Roberts et al., 1989) . Several important questions linking Gli genes to cancer remain: (1) Does GLI1 overexpression in tumors (herein meaning any focal abnormal growth) result from gene ampli®cation (due to genetic instabilities in the tumor), from SHH-pathway activation, or both?; (2) Do all tumors that involve abnormal Hh signaling also involve GLI genes, and is GLI2 involved? and (3) How does the cellular context and status of SHH signaling aect the activity of GLI proteins in tumors that involve GLI gene mis-regulation? Understanding the answers to these questions has obvious implications when considering GLI and/or SHH as therapeutic targets for tumor treatment.
Evidence that implicates Gli genes in tumor formation
Mutations that result in inappropriate activation of the Shh pathway have been shown to occur in several human diseases (see Goodrich and Scott, 1998, for review) . In Basal Cell Nevus Syndrome, which results from loss-of-function mutations in human PTC, there is a predisposition to medulloblastomas (pediatric tumors of the cerebellum and brainstem) and basal cell carcinoma's (BCCs), the most common type of cancer in Caucasians (see Goodrich and Scott, 1998) . Similarly, PTC loss of function and SMO activating mutations have been detected in some non-syndromic (sporadic) BCCs (Xie et al., 1998) . In addition, a high frequency of GLI1 over-expression is associated with human BCC samples (Dahmane et al., 1997) . Overexpression of Shh in transgenic mice, or in cultured human ®broblasts, can result in BCC-like tumors (Fan et al., 1997; Oro et al., 1997) . These results provide strong evidence that BCCs result from abnormal or unregulated SHH signaling in the skin.
Of the three vertebrate Gli genes, the involvement of Gli1 in tumor formation has been the most thoroughly investigated. Cell culture and transgenic experiments with Gli1 have shown it is capable of both activating Shh target genes and inducing cell proliferation in the mouse CNS, while in frog skin it is capable of inducing tumors (Hynes et al., 1997; Dahmane et al., 1997) . Moreover, GLI1 can transform ®broblasts in cooperation with the adenovirus gene E1A (Ruppert et al., 1991) . It is not clear, however, if GLI1 over-expression on its own can induce the formation of true BCCs, or whether it primarily functions to stimulate cell proliferation and that cooperating or parallel pathways must also be activated for tumor progression (Figure 4) .
The transformation of normal epithelial cells into tumors likely involves defects in at least three or four basic cellular processes, including mitogen response, cell cycle control, and senescence (Hahn et al., 1999) . Since Shh/Gli signaling can induce cell proliferation, mutations activating full-length GLI protein function likely contribute to tumorogenesis by stimulating this pathway in abnormal contexts. This observation raises the possibility that cell cycle genes could be targets of Gli proteins, or that Gli proteins may normally interact with cell cycle proteins or have cell-cycle dependent activities. It is also likely that the Shh pathway can aect more than one of the several biochemical Figure 4 Role of the Shh/Gli pathway in tumors. GLI1 overexpression in tumors could result from gene ampli®cation as a result of genetic instability within tumor cells, or activation of the Shh pathway (e.g., by SHH upregulation, loss of PTC function, activation of SMO mutation, or GLI2 or GLI3 Nterminal mutations). In the latter case, SHH pathway activation could result in the activation of a GLI-independent pathway that might also contribute to tumor formation. In some cell types, GLI1 overexpression could activate endogenous SHH expression. Both pathways likely require further secondary mutations in order for tumor progression pathways that must be altered in order to initiate tumor formation. For example, cell adhesion genes may be targets of Hh signaling (Rodriquez and (Figure 4) . However, tumor progression likely requires additional defects in cooperating pathways.
The only documented strict association of a mutation in a GLI gene with tumor formation is with GLI3. In PHS, which is caused by a frameshift mutation in GLI3, benign midline tumors of the ventral forebrain, known as hypothalamic hamartomas, often form (Kang et al., 1997) . Hypothalamic hamartomas seem to result from the abnormal proliferation of midline hypothalamic cell types that ultimately dierentiate and fail to progress into aggressive, metastatic tumors. The mutation in PHS maps to the C-terminus of the GLI3 gene downstream of the zinc-®nger coding region, and would be predicted to give rise to a C-terminally truncated protein with constitutive repressor activity (Biesecker, 1997; Shin et al., 1999) . This possibility is supported by the fact that in GCPS (which likely involve null GLI3 mutations) patients do not develop hypothalamic hamartomas (Biesecker, 1997).
GLI proteins: context-dependent functions in cancer?
Based on the association of GLI1 overexpression with BCC tumors, and the model that GLI1 functions only as a transcriptional activator that is not proteolyzed, whereas GLI2 and GLI3 might function as both activators and repressors, it would be predicted that GLI1 functions primarily as an oncogene if tumors arise due to its overexpression. GLI2 and GLI3, however, could function either as oncogenes or tumor-suppressors, depending on the type of mutation and cellular context. Although a role for GLI2 in tumor formation has not been documented, based on its similar properties to GLI1 and GLI3, it also likely plays a role in the formation or progression of tumors resulting from SHH pathway activation. Thus, the ability to directly assay the structure of GLI proteins in tumors will be required to determine whether downstream genes are activated or repressed. Since Gli1 appears to primarily function as an activator, a more straightforward role in tumors might be predicted than for Gli2 and Gli3. However, the originally-isolated human GLI1 cDNA isolated from a glioblastoma contains putative point mutations that, although they lead to conservative amino-acid substitutions, when the cDNA is expressed in cell lines the protein localizes abnormally to the nucleus (Kinzler and Vogelstein, 1990; Hynes et al., 1997) .
Gli gene targets?
Misregulation of GLI genes in abnormal contexts might activate other pathways than those previously identi®ed as being downstream of SHH, and these alternative pathways may contribute to tumor formation. Only a small number of candidate Gli target genes have been identi®ed in vertebrates, and one, the forkhead-containing transcription factor HNF3b expressed in the CNS (Sasaki et al., 1997) , is not upregulated in BCCs, whereas GLI1 is (Dahmane et al., 1997) . Interestingly, one target of the C. elegans Gli homologue tra-1 appears to be the egl-1 gene, which promotes cell death, but is repressed by Tra-1 in some cells (Conradt and Horvitz, 1999) . Similar Gli target genes in vertebrates would have obvious implications for the aects of mis-regulated Gli gene expression in tumor formation and/or progression. Alternatively, although GLI1 ampli®cation in tumors indicates the possible activation of SHH targets, it does not necessarily mean that GLI1 itself contributes primarily to tumor formation or progression, or predict downstream target activation, since the aected tissue may not be competent to respond to GLI proteins. In addition, the outcome of GLI1 (or SHH) misexpression could also depend on which forms of GLI2 and GLI3 are expressed. Consistent monitoring of the currently known elements of the Shh pathway, as well as the identi®cation of speci®c GLI protein targets in dierent tumor types, will be necessary to determine the consequences of inappropriate pathway activation.
